Because their spread through the brain correlates with cognitive decline and neurodegeneration, tau lesions serve as markers for staging disease and for recognizing nerve cell populations differentially vulnerable or resistant to AD pathogenesis. This evidence concerns the gene MAPT and Alzheimer disease.